STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
about
Regulation and function of AMPK in physiology and diseasesNeutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma.RNA-Seq Analysis of the Antioxidant Status and Immune Response of Portunus trituberculatus Following Aerial Exposure.Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.Functional characterization of AMP-activated protein kinase signaling in tumorigenesis.Inflammation as a driver and vulnerability of KRAS mediated oncogenesisPredictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.The immune contexture in cancer prognosis and treatment.Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation.MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.Stromal Lkb1 deficiency leads to gastrointestinal tumorigenesis involving the IL-11-JAK/STAT3 pathway.Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.Implications of the tumor immune microenvironment for staging and therapeutics.Mechanisms of resistance to immune checkpoint inhibitors.Modulation of immunosurveillance by tumor-intrinsic genomic alterations.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis.'Genotype/immunotype' correlations in resected NSCLC.Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Cytokines, breast cancer stem cells (BCSCs) and chemoresistanceMutations and PD-1 Inhibitor Resistance in -Mutant Lung AdenocarcinomaExpression profiling of ubiquitin-related genes in LKB1 mutant lung adenocarcinomaAutochthonous murine models for the study of smoker and never-smoker associated lung cancers
P2860
Q26740291-88953C69-AB14-44A1-89E3-439FA86FDBB5Q33816141-94B81E75-1CC4-4D28-B0C4-5F679C431591Q36283286-59FB176B-91D1-432A-8DAC-36E690C4AF98Q36951807-642555B0-078F-42F5-ACEF-86FCB16FBC38Q37277324-C40118DF-1DD5-49C6-BB2E-8354A687EAE0Q37677409-0B12A96F-B51E-461D-A7C1-E014702983C6Q38437577-35E5026F-64E2-440F-A173-408F1E92EB8AQ38708958-2A157416-7613-4185-8B1D-5ED340CEDB58Q38797202-560733BE-C074-4B4A-87BA-66AD75FBB71CQ38807302-EBEFAB2F-A6BE-41AA-9CC5-48B45339C352Q38864070-C035CCB9-8ED9-4BC8-9D0B-79C033257F90Q38938285-BD472637-B25A-437F-906B-392BCD17D014Q39456999-5E19BFDA-F3C2-47D3-9D7C-9BCA2B40CDACQ40805952-2962FB35-6D94-4A82-8995-6A4E11F9C186Q41008660-5FFA0F1A-342C-4AE7-A102-22F381DE256DQ41706974-C1A9A905-CAD4-4062-A9D6-6C1AB2AB90BEQ41819380-56F23D01-2F2D-4D63-BE94-B83706C32331Q42820759-E487CAEA-4C90-479F-AA7C-439E9D27B126Q47323319-9A8E87FA-ABBE-4AF8-A0E1-B0FFF2F8383AQ47373003-04AA75ED-53B9-48B9-A54B-35800591873BQ47423597-89633793-CE7B-4D5D-A98F-BA5206565300Q47592007-D3FE755A-5BA2-4D78-8513-EC3047C3ECC4Q49537326-7FF2E49F-D704-4CD3-B6AE-C39992103AFBQ49557912-1A21485D-5DFD-4D88-899B-9E890B3C3330Q49887897-7C1F31D8-8698-4FDE-970E-9AC17196AF44Q50027697-0E750982-3F88-4747-BBF8-BD399CAA800BQ52605888-869E4C07-C5E1-4613-AF14-0B6FD261DC56Q53600744-D2931D5D-FC55-4C51-8FF8-A0790960239BQ55209571-F36CDDA6-9D60-49E2-A1B5-A18C043C82A7Q55515297-A00129A3-C289-4F65-BCDE-18289869F6E0Q57106445-6B2FB210-C9F2-41F5-B6DA-E4461FADEC22Q57232070-7D42BB4B-0FAE-4FA8-AA14-055B456ACF13Q58763474-59D9F267-3E7B-4140-AB19-67A9FCD50080Q58804389-238BDB44-1BB7-4B18-AABB-5EDFC4B8799E
P2860
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
STK11/LKB1 Deficiency Promotes ...... e Lung Tumor Microenvironment.
@en
type
label
STK11/LKB1 Deficiency Promotes ...... e Lung Tumor Microenvironment.
@en
prefLabel
STK11/LKB1 Deficiency Promotes ...... e Lung Tumor Microenvironment.
@en
P2093
P2860
P50
P1433
P1476
STK11/LKB1 Deficiency Promotes ...... he Lung Tumor Microenvironment
@en
P2093
Abigail Altabef
Amir R Aref
David A Barbie
Edwin R Parra-Cuentas
F Stephen Hodi
Ferdinandos Skoulidis
Glenn Dranoff
Gordon J Freeman
Grit S Herter-Sprie
Haikuo Zhang
P2860
P304
P356
10.1158/0008-5472.CAN-15-1439
P407
P577
2016-02-01T00:00:00Z